Literature DB >> 196572

Type specificity and use of human sera for rapid typing of herpes simplex virus isolates by an indirect peroxidase-labeled antibody technique: a comparison with three other methods.

G Gerna, J Ditmore, R W Chambers.   

Abstract

Human sera from patients showing seroconversion following a primary herpes simplex virus type 1 (HSV-1) or HSV type 2 (HSV-2) infection, as well as 19S and 7S fractions obtained from the same sera, have been used for typing 191 HSV isolates by an indirect peroxidase-labeled antibody (PLA) method. Typing has also been performed on all of the isolates using a microneutralization (MN) and the indirect hemagglutination (IHA) inhibition test. Furthermore, 30 isolates have been typed by a plaque method. Results obtained with the PLA method was in complete agreement with those of the other two procedures. The PLA method is rapid and simple, offers easy interpretation and a permanent record of results.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 196572     DOI: 10.1007/bf01314384

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  26 in total

1.  The immunoperoxidase technique for rapid human cytomegalovirus identification.

Authors:  G Gerna; A Vasquez; C J McCloud; R W Chambers
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

2.  Herpes simplex virus microneutralization: a simplification of the test.

Authors:  H Stalder; M N Oxman; K L Herrmann
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

3.  Use of immunoperoxidase for the rapid identification of human myxoviruses and paramyxoviruses in tissue culture.

Authors:  D R Benjamin; C G Ray
Journal:  Appl Microbiol       Date:  1974-07

4.  [New possibility of rapid diagnosis by photonic immunoperoxidase microscopy human cell infection by the Herpex simplex hominis virus].

Authors:  E Kurstak; M Lauzon; C Kurstak; R Morisset
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-06-05

5.  Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2).

Authors:  A J Nahmias; I DelBuono; K E Schneweis; D S Gordon; D Thies
Journal:  Proc Soc Exp Biol Med       Date:  1971-10

6.  Properties of plaque variants of herpes virus hominis strains of genital origin.

Authors:  K Munk; G Ludwig
Journal:  Arch Gesamte Virusforsch       Date:  1972

7.  Late 19S rabbit antibody neutralization test for differentiating herpes simplex virus types 1 and 2.

Authors:  B Hampar; L M Martos; M Chakrabarty; M A Burroughs
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

8.  A serologic study of herpesvirus hominis strains by microneutralization tests.

Authors:  F P Pauls; W R Dowdle
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

9.  Rubella virus identification in primary and continuous monkey kidney cell cultures by immunoperoxidase technique.

Authors:  G Gerna
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

10.  Indirect hemagglutinating antibody response to Herpesvirus hominis types 1 and 2 in immunized laboratory animals and in natural infections of man.

Authors:  A F Back; N J Schmidt
Journal:  Appl Microbiol       Date:  1974-09
View more
  3 in total

1.  Comparison of cytopathic effect and an enzyme-linked immunosorbent assay using monoclonal antibodies for typing herpes simplex virus isolates.

Authors:  E Druyts-Voets
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

2.  Typing of herpes simplex virus isolates by enzyme-linked immunosorbent assay: comparison between indirect and double-antibody sandwich techniques.

Authors:  G Gerna; M Battaglia; M G Revello; M T Gerna
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

3.  Typing of herpes simplex virus with type-specific human immunoglobulin M in an indirect immunofluorescence assay.

Authors:  S L Spruance; C A Golden; E R Kern; M E Katz; F Chow
Journal:  J Clin Microbiol       Date:  1982-02       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.